Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 35,409 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: PARKINSON DISEASE (Disorder)
Interventions: Prebiotic fiber blend; Dietary Supplement
Lead sponsor: Sorridi Therapeutics; Industry
Eligibility: 60 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Northbrook, Illinois

Conditions: Reading Disability
Interventions: GraphoLearn reading intervention, Math control intervention; Other
Lead sponsor: University of Connecticut; Other
Eligibility: 6 Years to 11 Years
Enrollment: 315 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma, Epithelial Ovarian Carcinoma, Mesothelioma, Gastroenteropancreatic Neuroendocrine Tumor, SCLC, Gastric Carcinoma, Pancreatic Adenocarcinoma, Colorectal Carcinoma, Neuroendocrine Tumors
Interventions: Lurbinectedin, Irinotecan; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 4
States / cities: Santa Monica, California • Boston, Massachusetts • Houston, Texas

Conditions: HIV Infection
Interventions: 3MV, PCC, Emtricitabine/tenofovir (FTC/TDF (Truvada®)); Behavioral · Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 22 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 12
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more

Conditions: Influenza
Interventions: 2016-2017 Influenza Vaccine; Biological
Lead sponsor: Emory University; Other
Eligibility: 20 Years to 30 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Macular Degeneration, Choroidal Neovascularization
Interventions: Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: PF-05175157; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Breast Neoplasms
Interventions: CP-751,871, exemestane, Fulvestrant; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 33
States / cities: La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 10 more

Conditions: Obesity &Amp; Overweight
Interventions: Cardiovascular Exercise, Butyrate; Behavioral · Dietary Supplement
Lead sponsor: Texas Christian University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Firearm Safety
Interventions: Be SMART, Control: TSE, Be SMART + MD review; Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: Not listed
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Solid Tumors, GI Cancer
Interventions: CGX1321, Pembrolizumab, encorafenib, cetuximab; Drug
Lead sponsor: Curegenix Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 25
States / cities: Long Beach, California • Santa Rosa, California • Denver, Colorado + 21 more

Conditions: Achondroplasia
Interventions: BMN 111, Normal Saline; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 22 Years to 45 Years · Male only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Elevated Caregiver Strain, Dementia Caregiver, Caregiver Stress
Interventions: Caring Together, Savvy Caregiver; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension, Pulmonary
Interventions: GSK2586881; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Dallas, Texas

Conditions: Glioblastoma
Interventions: Optune; Device
Lead sponsor: Baylor Research Institute; Other
Eligibility: 22 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Echocardiography Test, Fludarabine, Leukapheresis, Single Agent Therapy; Procedure · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Rheumatologic Disorder, Inflammatory Bowel Diseases, Immune Complex Diseases
Interventions: Influenza vaccine; Biological
Lead sponsor: Stony Brook University; Other
Eligibility: 3 Years to 22 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: East Setauket, New York

Conditions: Stage III or Stage IV Melanoma
Interventions: CADI-05; Biological
Lead sponsor: Cadila Pharnmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Allentown, Pennsylvania

Conditions: Healthy
Interventions: LY3154885 - Capsule, Placebo - Capsule, Itraconazole, LY3154885 - Tablet; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Stroke, Balance; Distorted
Interventions: Body weight support system control group, Body weight support system with balance perturbations; Device
Lead sponsor: Gaylord Hospital, Inc; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Wallingford, Connecticut

Conditions: Periodontitis
Interventions: SRP + MM, Scaling and Root Planing (SRP); Procedure
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Pancreatic Cancer
Interventions: Stereotactic Body Radiotherapy, Gemcitabine, 4D pancreatic protocol CT scan, FDG PET scan; Radiation · Drug · Other
Lead sponsor: Albert Koong; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Solid Tumor
Interventions: TL118 Capsule; Drug
Lead sponsor: Teligene US; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Glendale, California • Dallas, Texas • Houston, Texas + 1 more

Conditions: Cancer, Solid Tumor
Interventions: Personalized Synthetic Long Peptide Vaccine; Biological
Lead sponsor: Jaime Leandro Foundation for Therapeutic Cancer Vaccines; Other
Eligibility: 12 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 6
States / cities: Beverly Hills, California • San Francisco, California • Santa Monica, California + 3 more

Search by objective public record fields.

Open Label Single Arm Prebiotic Pilot Trial SR001

Neurocognitive Factors in EdTech Intervention Response

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis

The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

A Healthy Volunteer Study To Assess Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

Can Gut Bacteria Predict Who Benefits Most From Exercise? A Gut Supplement to Help Exercise Non-Responders

Pediatric Inpatient Firearm Safety Study

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers

Leveraging Interventions for Caregiver Growth, Health, Training, Empowerment and Navigation: Comparing Group Behavioral Interventions to Improve Dementia Caregiver Strain

A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH)

Prognosis and Therapeutic Biomarkers for Glioblastoma Patients

BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

Flu Vaccine Response in Patients on Biologic Therapies

Safety Study of CADI-05 in Patients With Advanced Stage Melanoma

A Study of LY3154885 in Healthy Participants

Explorations of the Benefits of the ZeroG TRiP System to Improve Balance in Patients Following Stroke

Influence of SRP With MM on the Composition and Functional Characteristics of Subgingival Microbiome Communities

Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors